{"schema_version":"secwatch.filing_event.v1","accession":"0001799191-23-000029","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.283754+00:00","generated_at":"2026-06-11T23:01:42.871951+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TOI Q2 revenue up 32% to $80M, net loss widens to $16.9M, reaffirms FY 2023 guidance","bullets":["Revenue of $80M (+32% YoY); gross profit $15M (+36%); gross margin 18.8% vs 18.3%.","Net loss of $16.9M vs $5.5M loss in prior year; EPS $(0.19) vs $(0.06).","Adjusted EBITDA $(6.9)M, flat YoY; cash & investments $98M as of June 30, 2023.","Acquired Southland Radiation Oncology Network; patient visits up 14%, oral drugs dispensed up 38% YoY.","Reaffirmed full-year 2023 guidance; management cites strong topline growth and momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001799191-23-000029","json":"https://secwatch.observer/filing/0001799191-23-000029.json","markdown":"https://secwatch.observer/filing/0001799191-23-000029.md","text":"https://secwatch.observer/filing/0001799191-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000029/0001799191-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000029/toi-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:01:42.871951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c43b97c1fe694f14ccf31e0fb83c97a8ee2cae6","claim":"Oncology Institute, Inc. updated its three months ended June 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On August 8, 2023, The Oncology Institute, Inc. (the \"Company\") issued a press release announcing its financial results for the three months ended June 30, 2023 and certain other financial information.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000029/0001799191-23-000029-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}